| Identification | Back Directory | [Name]
Hexanoic acid, (1R)-1-[2-[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester | [CAS]
245515-64-4 | [Synonyms]
CRX-526
Hexanoic acid, (1R)-1-[2-[[(1S)-1-carboxy-2-[[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]-2-[[(3R)-1-oxo-3-[(1-oxohexyl)oxy]tetradecyl]amino]-4-O-phosphono-β-D-glucopyranosyl]oxy]ethyl]amino]-2-oxoethyl]dodecyl ester | [Molecular Formula]
C69H127N2O19P | [MOL File]
245515-64-4.mol | [Molecular Weight]
1319.74 |
| Hazard Information | Back Directory | [Uses]
CRX-526 is a TLR4 antagonist that can block the interaction of lipopolysaccharide (LPS, HY-D1056) with the immune system, including preventing the expression of pro-inflammatory genes stimulated by LPS, as well as blocking the release of TNF-α induced by LPS. CRX-526 exhibits anti-inflammatory effects in two mouse models of colitis (namely, the dextran sodium sulfate-induced colitis model and the multidrug resistance gene 1a-deficient mouse model)[1]. | [References]
[1] Fort MM, et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol. 2005 May 15;174(10):6416-23. DOI:10.4049/jimmunol.174.10.6416 |
|
|